FDA
-
-
-
-
-
-
-
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNuĀ® for Knee Osteoarthritis Pain
-
-
-
-
-
-
-
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
-
-
-
-
-
-
-
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
-
-
-
-
-
-
-
Organogenesis Shares ReNuĀ® Program Update
-
-
-
-
-
-
-
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sleep Number, Revance, Paysafe, and Organogenesis and Encourages Investors to Contact the Firm
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

